Hydromorphone Hydrochloride Tablet, Extended Release
Product Images NDC 31722-121

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Hydromorphone Hydrochloride (NDC 31722-121). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

12 mg (12 mg 100 Ct)

Hydromorphone Hydrochloride Extended-Release Tablets 12 mg oral tablets, medication label from Camber Pharmaceuticals, Inc. The label states a package size of 100 tablets, for opioid tolerant patients only, and indicates the tablets are to be taken once daily. Includes storage instructions and manufacturer details.*

FDA Label Image

16 mg (16 mg 100 Ct)

Label for hydromorphone hydrochloride extended-release tablets, 16 mg strength, oral dosage form. The label shows 100 tablets in the package, intended for opioid tolerant patients only. Manufactured for Camber Pharmaceuticals, Inc. and by Ascent Pharmaceuticals, Inc. The label includes usage instructions such as swallowing tablets whole and storage conditions.*

FDA Label Image

32 mg (32 mg 100 Ct)

Label for hydromorphone hydrochloride extended-release tablets, 32 mg strength, manufactured by Camber Pharmaceuticals, Inc. The label states the product is for oral use, in a package of 100 tablets, with prescription-only status and use limited to opioid tolerant patients. Additional instructions note swallowing tablets whole, storage conditions, and manufacturer details.*

FDA Label Image

8 mg (8 mg 100 Ct)

Packaging label for Hydromorphone Hydrochloride Extended-Release Tablets 8 mg by Camber Pharmaceuticals, Inc. The label states "Once Daily" dosing and contains 100 tablets. It includes warnings such as "For opioid tolerant patients only" and instructions not to break, crush, or chew the tablets. Manufacturer information for Camber Pharmaceuticals and Ascent Pharmaceuticals is also shown.*

FDA Label Image

Fig-1 (Figure 1)

A line graph depicting plasma hydromorphone concentration (ng/mL) over time (hours) comparing hydromorphone hydrochloride extended-release tablets 16 mg every 24 hours versus HMIR 4 mg every 6 hours. The graph shows concentration fluctuations over the time interval 96 to 120 hours.*

FDA Label Image

Fig-2 (Figure 2)

A line graph depicting the percentage of patients improved on the vertical axis against the percent of reduction/improvement in pain on the horizontal axis. It compares Hydromorphone Hydrochloride Extended-Release Tablets and HMIR at Week 12, showing trends in patient pain improvement for each treatment over a range of pain reduction percentages.*

FDA Label Image

Structure (Structure)

Chemical structure of hydromorphone hydrochloride, showing its molecular framework with labeled bonds and atoms, including an HCl component.*

FDA Label Image

Table-5 (Table 5)

A data table presenting pharmacokinetic parameters for hydromorphone hydrochloride extended-release tablets at various dosages, including single doses (8 mg to 64 mg) and multiple dose regimens. Parameters include median time to maximum concentration (Tmax), maximum concentration (Cmax), area under the curve (AUC), and half-life (T1/2), with values provided alongside ranges or standard deviations where applicable.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.